undamentalytics Newsletter
Sign in

Stoke Therapeutics, Inc. income statement

In fiscal 2025, Stoke Therapeutics, Inc. reported revenue of $184m, up 404.5% on the year before, operating income of −$20.6m (a -11.2% margin) and net income of −$6.9m, or −$0.12 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1293718428
Research and development788289138169
Selling, general and administrative——496782
General and administrative3941———
Operating income−104−115−101−21−223
Interest expense—0000
Income tax———0−1
Net income−101−105−89−7−208
Diluted EPS−$2.60−$2.38−$1.65−$0.12−$3.35
Diluted shares (average)39m44m54m59m62m
EBITDA−103−112−99−19−222

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: GLUE vs STOKSTOK vs TNXPARCT vs STOKABEO vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Stoke Therapeutics, Inc.